176 results about "Ketamine" patented technology

Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.

This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE.

The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.

An NMDA antagonist (such as ketamine) is administered with a safener (such as clonidine) in patients suffering from neurologic disorders other than pain. The ketamine is adminsitered at a dosage that causes slurred speech, for a span of several days. This treatment enables a patient's nervous system to return to a healthy “set point”, also called an improved stable neural homeostasis, in a manner similar to a broken bone healing itself if protected from jostling and reinjury by a cast. In at least some patients, this treatment can ease problems such as addictions to illegal or pain-killing drugs, nicotine, or alcohol, compulsive or criminal behavioral problems, severe depression, obsessive-compulsive disorders, phobias, etc. It may also provide some relief in some patients for problems such as chronic fatigue, chemical sensitivities, allergies, autoimmune disorders, and diabetes.

The present invention relates to methods and compositions for the treatment of pain, in a preferred embodiment relating to the oral transmucosal administration of S-Ketamine, its salts or derivatives.

A drug that inhibits NMDA receptors (such as ketamine, a surgical anesthetic) is continuously administered to patients suffering from neuropathic pain. Unless the NMDA antagonist drug has inherent safening activity, this treatment requires a “safener” drug to prevent the neurotoxic side effects of NMDA antagonists. One class of safener drugs that increase the efficacy of the treatment include alpha-2 adrenergic agonists, such as clonidine. The treatment lasts for several days and nights, continuously. A maximum tolerated dosage is titered for each patient, such as by observing slurring of speech, and the patient does not lose consciousness except during normal sleep. Magnesium and/or drugs that inhibit ketamine-degrading enzymes can also be used. Patients who suffered for years from chronic intractable pain emerged from this treatment with apparently permanent relief, or with lasting reductions in their levels of pain.

The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions. A priority GENOPROFILE is measured and directs the customization of a subsequent nutraceutical to act as a therapeutic modality. Specifically the treatment includes slow attenuation of the pain medication by incorporating orals (shakes, liquid beverages, pills, tablets, troche, ointments etc.), Intramuscular, Intravenous, intra-rectal and any form necessary to deliver a sufficient amount of an anti-craving and anti-stress nutraceutical. Moreover, the invention includes examples of novel analgesic ointments coupling Synaptamine and such analgesic and other anesthetic compounds including but not limited to Gabapentin, Ketamine, Baclofen, Ketoprofen, Amitriptyline, Lidocaine, Cyclobenzapine, Diclofenac, Menthol, Camphor and Capsaicin. The GENOPROFILE will be used to determine pain sensitivity Intolerance.

An analgesic composition, is disclosed which comprises a mixture of piroxicam, dexamethasone, ketamine, lidocaine injection, dimethyl sulfoxide, gabapentin and Vanicream™, preferably in the form of a cream or ointment. The composition is applied topically for the relief of pain of arthritis, neuropathy, post-herpetic (shingles) conditions, sore muscles, tendons and ligaments, and local reactions to insect bites or stings.

Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and can be administered to subjects to treat various neuropathies.

A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults.

The invention discloses a hapten and complete antigen used for ketamine detection and antibody preparation. The invention also discloses an anti-ketamine monoclonal antibody prepared by the complete antigen and a colloidal gold-labeled ketamine monoclonal antibody immunoassay plate used for detecting ketamine in drugs or urine, etc., human samples. Compared with HPLC method, the invented detection plate is simple, portable and easy to carry, and can be used for spot detection without need of expensive equipment. The whole detection for ketamine by using the detection plate can be completed in 10 minutes with sensitivity up to 50 ng and with no cross reaction with 39 kinds of common pharmaceuticals, drugs, and ketamine metabolites in vivo.

A testing strip includes an elongated strip carrier and a reagent on the carrier. The reagent reacts with one of Rohypnol, Ketamine, GHB, GBL, and 1,4-butanediol to change color indicating the presence of Rohypnol, Ketamine, GHB, GBL, and 1,4-butanediol. A dispenser for dispensing testing strips is also disclosed. The dispenser includes a container and at least one testing strip including an elongated strip carrier and a reagent on the carrier that reacts with one of Rohypnol, Ketamine, GHB, GBL, and 1,4-butanediol to change color indicating the presence of Rohypnol, Ketamine, GHB, GBL, and 1,4-butanediol.

The invention relates to precoated sand used for sand prevention for intermediate and low temperate oil deposit and a preparation method thereof. The preparation method comprises the following steps of: 1)evenly mixing 40-50 parts of epoxy resin and 12-25 parts of solvent to prepare solution; 2) adding 2-4 parts of ketamine curing agent into the solution to be evenly mixed; 3) evenly mixing 1.6-2.2 parts of coupling agent and 1000 parts of quartz sand; 4) adding the solution into the quartz sand to be evenly mixed; and 5) dispersing pre-packaged sand, rolling to scatter the sand to be packaged after the sand to be packaged is thoroughly dried, and bagging to be packaged in a sealing mode. The precoated sand prepared with the preparation method disclosed by the invention has the advantages of small use amount of required sand consolidation agent and low medicament cost, and the volatile polyamine curing agent with pungent smell is modified into latent curing agent which is free from peculiar smell and is easy to store. The precoated sand has a simple preparation technology, can be used without being prepared, can be stored for a long time in the dry place, has the advantages of good temperature resistance, ageing resistance and corrosion resistance, high solidified sand core strength and good permeability.

A method for treating age related macular degeneration (AMD) using an insulin preparation applied topically to the conjunctival sac of the affected eye. Another aspect of this invention is using antiangiogenic adjuvant therapeutic agents such as bevacizumab, ranibizumab, pegaptanib, etanercept, instilled in to the afflicted eye conjunctival sac with insulin to prevent further formation of new blood vessels, and shrink the existing pathologically formed blood vessels and reduce the edema in wet AMD. This method incorporates putting the patients on low fat diet, aerobic exercise, ketamine-a NMDA blocker, reducing the blood cholesterol using adjuvant therapeutic agents selected from Statins, that are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A, (i.e. HMG-Co A) reductase which in turn reduce drusen formation that leads to AMD, combined with insulin ophthalmic drops.

The invention provides an application of a combined drug composition of ketamine or S-(+)-ketamine or a pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or a pharmaceutically acceptable salt of escitalopram, to the preparation of drugs for treating major depressive disorder. The major depressive disorder can be major depressive disorder breaking out for the first time, major depressive disorder breaking out again or refractory depression. The invention furthermore provides an application of ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine to the preparation of the drugs for treating the major depressive disorder, and a drug preparation containing ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or the pharmaceutically acceptable salt of escitalopram. Ketamine and conventional antidepressants are used together; and a proper amount of ketamine is intravenously injected once at first day of start of treatment, so that the anti-depression effect of oral antidepressants can be effectively improved, the effect display lag period is remarkably shortened, and suicidal actions of patients can be remarkably reduced.

The invention belongs to the technical field of analytical chemistry, and relates to a method for rapidly assaying four amphetamines (amphetamine, methamphetamine, methylene-dioxy-amphetamine and methylene-dioxy-methamphetamine), ketamine, pethidine and methadone in blood and urine. The method is high in sensitivity and specificity and wide in linear range, can be used for qualitatively and quantitatively assaying analytes of unknown concentrations in the blood and the urine, and is simple and rapid to operate; according to the method, processes of extracting, and drying by evaporating are not required, and characteristics that a judicial expertise task is urgent and has a high requirement on assaying time can be met; an assaying system, provided by the invention, provides a new technical platform for drug assaying, and is easy to popularize and apply.

A process for preparing xanthiphenyl ketoamine or its salt includes such steps as reflux reaction of p-hydroxy benzylidenacetone, N-methyl piperethanamine hydrochloride and polyformaldehyde in absolute alcohol for 6-9.5 hr until fully solidifying, filtering, washing, recrystallizing 1-2 times, then drying to obtain xanthiphenyl ketoamine hydrochloride, neutralizing to obtain xanthiphenyl ketoamine, and reaction on acid to obtain the corresponding salt. Its advantages are simple process, high output rate and high purity.

Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack (Specifier), Agoraphobia, Generalized Anxiety Disorder, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, or fatigue, the method including administering a pharmaceutical composition containing an effective amount of an active agent, wherein the active agent is purified (2R,6R)-hydroxynorketamine, purified (2S,6S)-hydroxynorketamine, or a combination thereof, or a pharmaceutically acceptable saltthereof, together with a pharmaceutically acceptable carrier to a patient in need of such treatment.

Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

The invention discloses a rimsulfuron.haloxyfop-P-methyl water dispersible granule as a weed killer and a preparation method thereof, belonging to the technical field of weeding for plant protection. The rimsulfuron.haloxyfop-P-methyl water dispersible granule comprises the following components in percentage by mass: 10-20% of rimsulfuron, 5-10% of haloxyfop-P-methyl, 3-5% of wetting agent K12, 5-8% of ketamine as a dispersing agent, 5-7% of ammonium sulfate as a disintegrating agent, 5-10% of white carbon black as a carrier and the balance of light calcium carbonate as packing. The rimsulfuron.haloxyfop-P-methyl water dispersible granule can be used for preventing and controlling grassy weeds such as crab grass, moleplant seeds, annual broad-leaved weeds such as crowndaisy chrysanthemum, piemarker and the like and cyperaceae weeds such as cyperus rotundus and the like in a tobacco field. The rimsulfuron.haloxyfop-P-methyl water dispersible granule has the advantages of no need of specific equipment for a process, simplicity in operation, low preparation cost, little pollution to the environment, safety in storage and transportation, stable preventing effect and the like.